Compare GSK plc (GSK) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Charles Schwab Corporation Common Stock — how do they compare? GSK plc trades at $52.64 (market cap $101.34B), while Charles Schwab Corporation Common Stock trades at $102.84 (market cap $178.77B). The key difference: Charles Schwab Corporation Common Stock is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | SCHW | |
|---|---|---|
Market Cap | $101.34B | $178.77B |
Sector | Health | Financials |
52-Week High | $61.18 | $107.21 |
52-Week Low | $36.20 | $85.35 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Charles Schwab (SCHW) trades at $101.10, down 1.25% today, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI levels suggest potential near-term overbought conditions. Recent financial performance demonstrates robust revenue growth to $23.92 billion in 2025 and net income margin expansion to 37.99%, supported by strong trading activity and asset management fees.
The outlook remains positive with analyst consensus pointing to 25.9% upside potential to $123.71. Key catalysts include continued earnings growth and strong retail trading activity, while risks involve interest rate sensitivity and market volatility. With 58% of analysts maintaining buy ratings and improving cash flow trends, SCHW presents a compelling investment case for growth-oriented investors despite current valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
